289 related articles for article (PubMed ID: 22848655)
1. Crystal structure of the Sema-PSI extracellular domain of human RON receptor tyrosine kinase.
Chao KL; Tsai IW; Chen C; Herzberg O
PLoS One; 2012; 7(7):e41912. PubMed ID: 22848655
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the binding specificity of human Recepteur d'Origine Nantais (RON) receptor tyrosine kinase to macrophage-stimulating protein.
Chao KL; Gorlatova NV; Eisenstein E; Herzberg O
J Biol Chem; 2014 Oct; 289(43):29948-60. PubMed ID: 25193665
[TBL] [Abstract][Full Text] [Related]
3. The soluble sema domain of the RON receptor inhibits macrophage-stimulating protein-induced receptor activation.
Angeloni D; Danilkovitch-Miagkova A; Miagkov A; Leonard EJ; Lerman MI
J Biol Chem; 2004 Jan; 279(5):3726-32. PubMed ID: 14597639
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MSP-RON signaling pathway in cancer cells by a novel soluble form of RON comprising the entire sema sequence.
Ma Q; Zhang K; Yao HP; Zhou YQ; Padhye S; Wang MH
Int J Oncol; 2010 Jun; 36(6):1551-61. PubMed ID: 20428780
[TBL] [Abstract][Full Text] [Related]
5. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.
Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
J Biol Chem; 2008 Jul; 283(30):21267-77. PubMed ID: 18495663
[TBL] [Abstract][Full Text] [Related]
6. The ligand-binding face of the semaphorins revealed by the high-resolution crystal structure of SEMA4D.
Love CA; Harlos K; Mavaddat N; Davis SJ; Stuart DI; Jones EY; Esnouf RM
Nat Struct Biol; 2003 Oct; 10(10):843-8. PubMed ID: 12958590
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor.
Stamos J; Lazarus RA; Yao X; Kirchhofer D; Wiesmann C
EMBO J; 2004 Jun; 23(12):2325-35. PubMed ID: 15167892
[TBL] [Abstract][Full Text] [Related]
8. STK/RON receptor tyrosine kinase mediates both apoptotic and growth signals via the multifunctional docking site conserved among the HGF receptor family.
Iwama A; Yamaguchi N; Suda T
EMBO J; 1996 Nov; 15(21):5866-75. PubMed ID: 8918464
[TBL] [Abstract][Full Text] [Related]
9. Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering.
Bardelli A; Ponzetto C; Comoglio PM
J Biotechnol; 1994 Sep; 37(2):109-22. PubMed ID: 7765452
[TBL] [Abstract][Full Text] [Related]
10. Insights into function of PSI domains from structure of the Met receptor PSI domain.
Kozlov G; Perreault A; Schrag JD; Park M; Cygler M; Gehring K; Ekiel I
Biochem Biophys Res Commun; 2004 Aug; 321(1):234-40. PubMed ID: 15358240
[TBL] [Abstract][Full Text] [Related]
11. Crystal structure of the beta-chain of human hepatocyte growth factor-like/macrophage stimulating protein.
Carafoli F; Chirgadze DY; Blundell TL; Gherardi E
FEBS J; 2005 Nov; 272(22):5799-807. PubMed ID: 16279944
[TBL] [Abstract][Full Text] [Related]
12. RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP.
Gaudino G; Follenzi A; Naldini L; Collesi C; Santoro M; Gallo KA; Godowski PJ; Comoglio PM
EMBO J; 1994 Aug; 13(15):3524-32. PubMed ID: 8062829
[TBL] [Abstract][Full Text] [Related]
13. Functional consequences of the macrophage stimulating protein 689C inflammatory bowel disease risk allele.
Kauder SE; Santell L; Mai E; Wright LY; Luis E; N'Diaye EN; Lutman J; Ratti N; Sa SM; Maun HR; Stefanich E; Gonzalez LC; Graham RR; Diehl L; Faubion WA; Keir ME; Young J; Chaudhuri A; Lazarus RA; Egen JG
PLoS One; 2013; 8(12):e83958. PubMed ID: 24409221
[TBL] [Abstract][Full Text] [Related]
14. Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain.
Wang MH; Julian FM; Breathnach R; Godowski PJ; Takehara T; Yoshikawa W; Hagiya M; Leonard EJ
J Biol Chem; 1997 Jul; 272(27):16999-7004. PubMed ID: 9202013
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between RON receptor tyrosine kinase and other transmembrane receptors.
Danilkovitch-Miagkova A; Leonard EJ
Histol Histopathol; 2001 Apr; 16(2):623-31. PubMed ID: 11332718
[TBL] [Abstract][Full Text] [Related]
16. Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets.
Lu Y; Yao HP; Wang MH
Cancer Lett; 2007 Nov; 257(2):157-64. PubMed ID: 17889431
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
[TBL] [Abstract][Full Text] [Related]
18. Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells.
Thangasamy A; Rogge J; Ammanamanchi S
J Biol Chem; 2009 May; 284(21):14001-10. PubMed ID: 19307182
[TBL] [Abstract][Full Text] [Related]
19. Comparative characterization of the HGF/Met and MSP/Ron systems in primary pancreatic adenocarcinoma.
Vanderwerff BR; Church KJ; Kawas LH; Harding JW
Cytokine; 2019 Nov; 123():154762. PubMed ID: 31254927
[TBL] [Abstract][Full Text] [Related]
20. Integrative genomic analyses of recepteur d'origine nantais and its prognostic value in cancer.
Yu H; Yuan J; Xiao C; Qin Y
Int J Mol Med; 2013 May; 31(5):1248-54. PubMed ID: 23483216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
